Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon‐like peptide‐1 receptor agonists in Japanese patients with type 2 diabetes mellitus
Diabetes, Obesity and Metabolism · 2024-01 · 26 (1) · 262-274
DOI: 10.1111/dom.15312 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 12.10.2023. Verfasst von Shunichiro Tsukamoto und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Yokohama Foundation for Advancement of Medical Science, Uehara Memorial Foundation, Japan Society for the Promotion of Science.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To compare the therapeutic effects of glucose‐dependent insulinotropic polypeptide (GIP)/ glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) or GLP‐1RAs in Japanese patients with type 2 diabetes (T2D). Materials and Methods We systematically searched PubMed, MEDLINE, EMBASE, and the Cochrane Library up to July 2023. Randomized controlled trials (RCTs) that compared GLP‐1RAs or GIP/GLP‐1RAs in Japanese patients with T2D were selected. A network meta‐analysis was conducted to indirectly compare the treatments, focusing on efficacy in reducing glycated haemoglobin (HbA1c) levels and body weight (BW).
Results
A total of 18 RCTs were included in this analysis. Tirzepatide 15 mg showed the most significant reduction in HbA1c levels and BW compared with subcutaneous semaglutide 1.0 mg and oral semaglutide 14 mg (HbA1c: mean difference [95% confidence interval] −0.52 [−0.96; −0.08] and − 1.23 [−1.64; −0.81]; BW: −5.07 [−8.28; −1.86] and −6.84 [−8.97; −4.71], respectively). Subcutaneous semaglutide showed a superior reduction in HbA1c compared with oral semaglutide. Both subcutaneous and oral semaglutide were more effective than conventional GLP‐1RAs, such as dulaglutide, liraglutide and lixisenatide.
Conclusions
Among Japanese patients with T2D, tirzepatide showed the greatest effectiveness in reducing HbA1c levels and inducing weight loss. The study provides evidence to guide GLP‐1RA treatment strategies in Japanese patients with T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA.
- Department of Kampo Medicine, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Japan.
ORCID-Profile: Takayuki Yamada, Hiromichi Wakui
Förderung
- Yokohama Foundation for Advancement of Medical Science
- Uehara Memorial Foundation
- Japan Society for the Promotion of Science
Zitieren
APA
Tsukamoto, S., Tanaka, S., Yamada, T., Uneda, K., Azushima, K., Kinguchi, S., Wakui, H., & Tamura, K. (2024). Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon‐like peptide‐1 receptor agonists in Japanese patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 26(1), 262-274. https://doi.org/10.1111/dom.15312
Vancouver
Tsukamoto S, Tanaka S, Yamada T, Uneda K, Azushima K, Kinguchi S, et al. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon‐like peptide‐1 receptor agonists in Japanese patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2024;26(1):262-274. doi:10.1111/dom.15312
BibTeX
@article{Tsukamoto2024,
author = {Tsukamoto, Shunichiro and Tanaka, Shohei and Yamada, Takayuki and Uneda, Kazushi and Azushima, Kengo and Kinguchi, Sho and Wakui, Hiromichi and Tamura, Kouichi},
title = {Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon‐like peptide‐1 receptor agonists in Japanese patients with type 2 diabetes mellitus},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
volume = {26},
number = {1},
pages = {262--274},
doi = {10.1111/dom.15312}
}
EUVIMED